Targeting paraoxonase-1 in atherosclerosis

Bibliography

• Rajkovic MG, Rumora L, Barisic K. The paraoxonase 1, 2 and 3 in humans. Biochem Med 2011;21:122-30
   PubMed Web of Science ®Google Scholar
• Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmac 1998;31:329-36
   PubMedGoogle Scholar
• Mazur A. An enzyme in the animal organism capable of hydrolysing the phosphorus-fluorine bond of alkyl fluorophosphates. J Biol Chem 1946;164:271-89
   PubMed Web of Science ®Google Scholar
• Aldridge WN. Serum esterases 2 – an enzyme hydrolysing diethyl p-nitrophenylphosphate (E600) and its identity with the A-esterase of mammalian sera. Biochem J 1953;53:117-24
   PubMed Web of Science ®Google Scholar
• Davidson WS, Silva RAGD, Chantepie S, et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters- Relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009;29:870-6
   PubMed Web of Science ®Google Scholar
• Harel M, Aharoni A, Gaidukov L, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004;11:412-19
   PubMed Web of Science ®Google Scholar
• Primo-Parma SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498-509
   PubMedGoogle Scholar
• Rodriguez-Sanabria F, Rull A, Beltran-Debon R, et al. Tissue distribution and expression of paraoxonases and chemokines in the mouse: the ubiquitous and joint localisation suggest a systemic and coordinated role. J Mol Histol 2010;41:379-86
   PubMedGoogle Scholar
• Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004;37:1304-16
   PubMed Web of Science ®Google Scholar
• Reddy ST, Devarajan A, Bourquard N, et al. Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis? Curr Opin Lipidol 2008;19:405-8
   PubMedGoogle Scholar
• Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci 2004;107:435-47
   PubMed Web of Science ®Google Scholar
• Durrington PN. Hyperlipidaemia. Diagnosis and Management. 2nd edition. Butterworth Heinemann; London: 1995
   Google Scholar
• Steinberg D, Parthasarathy S, Carew TE. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. New Engl J Med 1989;320:915-24
   Google Scholar
• Lusis AJ. Atherosclerosis. Nature 2000;407:233-41
   PubMed Web of Science ®Google Scholar
• Chisholm GM, Penn MS. Oxidised lipoproteins and atherosclerosis. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease. Lippincott-Raven, Philadelphia; 1996. p. 129-49
   Google Scholar
• Endemann G, Stanton LW, Madden KS, et al. CD36 is a receptor for oxidised low density lipoprotein. J Biol Chem 1993;268:11811-16
   Google Scholar
• Rice-Evans C, Bruckdorfer KR. Free radicals, lipoproteins and cardiovascular dysfunction. Molec Aspects Med 1992;13:1
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
   PubMed Web of Science ®Google Scholar
• Shah PK. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL. Curr Opin Cardiol 2010;25:603-8
   PubMedGoogle Scholar
• Fisher EA, Feig JE, Hewing B, et al. High-density lipoprotein function, dysfunction and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2012;32:2813-20
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
   PubMed Web of Science ®Google Scholar
• Landmesser U. High Density Lipoprotein – should we raise it? Curr Vasc Pharmacol 2012;10:718-19
   PubMedGoogle Scholar
• Klimov AN, Kozhemyakin LA, Pleskov VM, Andreeva LI. Antioxidative effect of high density lipoproteins in the oxidation of low density lipoproteins. Bull Exp Biol Med (Russ) 1987;103:550-6
   Google Scholar
• Ohta T, Takata S, Morino Y, Matsuda I. The protective effects of lipoproteins containing apoprotein A-I on Cu2+-catalysed oxidation of human low-density lipoprotein. FEBS Letts 1989;257:435-8
   PubMed Web of Science ®Google Scholar
• Mackness MI, Abbott CA, Arrol S. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993;294:829-35
   PubMed Web of Science ®Google Scholar
• Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275-83
   PubMed Web of Science ®Google Scholar
• Klimov AN, Gurevich VS, Nikiforova AA, et al. Antioxidative activity of high-density lipoproteins in vivo. Atherosclerosis 1993;100:13-19
   PubMed Web of Science ®Google Scholar
• Klimov AN, Nikiforova AA, Kuzmin AA, et al. Is high density lipoprotein a scavenger for oxidised phospholipids of low density lipoprotein? Advances in Lipoprotein and Atherosclerosis Research, Diagnostics and Treatment. Gustav Fischer Verlag Jena 1998;78-82
   Google Scholar
• Chander R, Kapoor NK. High density lipoprotein is a scavenger of superoxide ions. Biochem Pharmacol 1990;40:1663-8
   PubMed Web of Science ®Google Scholar
• Kunitake ST, Jarvis MR, Hamilton RL, Kane JP. Binding of transition metals by apolipoprotein A-I containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc Natl Acad Sci USA 1992;89:6993-7
   PubMed Web of Science ®Google Scholar
• Navab M, Hama SY, Anantharamaiah GM, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidised low density lipoprotein: steps 2 and 3. J Lipid Res 2000;41:1495-508
   PubMed Web of Science ®Google Scholar
• Sattler W, Stocker R. Greater selective uptake by Hep G2 cells of high density lipoprotein cholesterylester hydroperoxides than unoxidised cholesterylesters. Biochem J 1993;294:771-6
   PubMed Web of Science ®Google Scholar
• Mackness MI, Durrington PN. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995;115:243-53
   PubMed Web of Science ®Google Scholar
• Hessler JR, Morel DW, Lewis LJ, Chisholm GM. Lipoprotein oxidation and lipoprotein induced cytotoxicity. Arteriosclerosis 1983;3:215-22
   PubMedGoogle Scholar
• Hessler JR, Robertson AL, Chisholm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979;32:213-29
   PubMed Web of Science ®Google Scholar
• Morel DW, Hessler JR, Chisholm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983;24:1070-6
   PubMed Web of Science ®Google Scholar
• Chung BH, Segrest JP, Smith K, et al. Lipolytic surface remnants of triglyceride-rich lipoproteins are cytotoxic to macrophages but not in the presence of high density lipoprotein. J Clin Invest 1989;83:1363-74
   PubMedGoogle Scholar
• Navab M, Imes SS, Hama SY, et al. Monocyte Transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991;88:2039-46
   PubMed Web of Science ®Google Scholar
• Mackness B, Mackness M. The antioxidant properties of high-density lipoproteins in atherosclerosis. Panminerva Med 2012;54:83-90
   PubMed Web of Science ®Google Scholar
• Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Letts 1991;286:152-4
   PubMed Web of Science ®Google Scholar
• Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-35
   PubMed Web of Science ®Google Scholar
• Aviram M, Billecke S, Sorenson R, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulphydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase alloenzymes Q and R. Arterioscl Thromb Vasc Biol 1998;10:1617-24
   Google Scholar
• Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase - Inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest 1995;96:2882-91
   PubMed Web of Science ®Google Scholar
• Ahmed Z, Ravandi A, Maguire GF, et al. Apolipoprotein AI promotes the formation of phosphatidylcholine core aldehydes that are hydrolysed by paraoxonase (PON1) during high density lipoprotein oxidation with a peroxynitrite donor. J Biol Chem 2001;276:24473-81
   PubMed Web of Science ®Google Scholar
• Draganov DI, La Du BN. Pharmacogenetics of paraoxonase: a brief review. Naunyn-Schmiedeberg's Arch. Pharmacology 2004;369:78-88
   Google Scholar
• Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. J Clin Invest 1998;101:1581-90
   PubMed Web of Science ®Google Scholar
• Deakin SP, Bioletto S, Bochaton-Piallat ML, James RW. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radic Biol Med 2011;50:102-9
   PubMed Web of Science ®Google Scholar
• Tavori H, Aviram M, Khatib S, et al. Paraoxonase 1 protects macrophages from atherogenicity of a specific triglyceride isolated from human carotid lesion. Free Rad Biol Med 2011;51:234-42
   PubMedGoogle Scholar
• Mackness B, Hine D, Liu Y, et al. Paraoxonase 1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. BBRC 2004;318:680-3
   PubMed Web of Science ®Google Scholar
• Younis NN, Soran H, Charlton-Menys V, et al. High-density lipoprotein impedes Glycation of low-density lipoprotein. Diabet Vasc Dis Res 2012; DOI 10.1177/1479164112454309
   PubMedGoogle Scholar
• Rozenberg O, Shih DM, Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 2005;181:9-18
   PubMed Web of Science ®Google Scholar
• Mackness B, Quarck R, Verreth W, et al. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:1545-50
   PubMed Web of Science ®Google Scholar
• Guns P-J, Van Assche T, Verreth W, et al. Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice with pre-existing atherosclerosis. Br J Pharmacol 2008;153:508-16
   PubMedGoogle Scholar
• Tward A, Xia YR, Wang XP, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002;106:484-90
   PubMed Web of Science ®Google Scholar
• Shih DM, Gu L, Xia Y-R, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998;394:284-7
   PubMed Web of Science ®Google Scholar
• Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalisation of paraoxonase, clusterin and apolipoprotein AI in the human artery wall with progression of atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:1233-8
   PubMed Web of Science ®Google Scholar
• Marsillach J, Camps J, Beltran-Debon R, et al. Immunohistochemical analysis of paraoxonases 1 and 3 in human atheromatous plaques. Eur J Clin Invest 2011;41:308-14
   PubMed Web of Science ®Google Scholar
• Rozenberg O, Shiner M, Aviram M, Hayek T. Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties. Free Rad Biol Med 2008;44:1951-9
   PubMed Web of Science ®Google Scholar
• Koren-Gluzer M, Aviram M, Meilin E, Hayek T. The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates beta-cell insulin release. Atherosclerosis 2011;219:532-7
   PubMedGoogle Scholar
• Mackness B, Durrington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003;107:2775-9
   PubMed Web of Science ®Google Scholar
• Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008;299:1265-76
   PubMed Web of Science ®Google Scholar
• van Himbergen TM, van der Schouw YT, Voorbij HAM, et al. Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women. Atherosclerosis 2008;198:408-14
   Google Scholar
• Ikeda Y, Inoue M, Suehiro T, et al. Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol 2009;46:239-42
   PubMedGoogle Scholar
• Troughton JA, Woodside JV, Yarnell JWG, et al. Paraoxonase activity and coronary heart disease in healthy middle-aged males: the PRIME study. Atherosclerosis 2008;197:556-63
   PubMedGoogle Scholar
• Birjmohun RS, Vergeer M, Stroes ES, et al. Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC- Norfolk prospective population study. PLoS ONE 2009;4:e6809
   Google Scholar
• Wang M, Lang X, Cui S, et al. Quantitative assessment of the influence of paraoxonase 1 activity and coronary heart disease. DNA Cell Biol 2012;31:975-82
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Suehiro T, Itahara T, et al. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol 2007;67:358-65
   PubMed Web of Science ®Google Scholar
• Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001;21:1451-7
   PubMed Web of Science ®Google Scholar
• Wheeler JG, Keavney BD, Watkins H, et al. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004;363:689-95
   PubMed Web of Science ®Google Scholar
• Tang WHW, Hartiala J, Fan Y, et al. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol 2012;32:2803-12
   PubMed Web of Science ®Google Scholar
• Jarvik GP, Rozek LS, Brophy VH, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype Arterioscl. Thromb Vasc Biol 2000;20:2441-7
   PubMed Web of Science ®Google Scholar
• Berrougui H, Loued S, Khalil A. Purified human paraoxonase-1 interacts with plasma membrane lipid rafts and mediates cholesterol efflux from macrophages. Free Rad Biol Med 2012;52:1372-81
   PubMedGoogle Scholar
• Mastorikuo M, Mackness B, Liu Y, Mackness M. Glycation of paraoxonase-1 inhibits its activity and impairs the ability of HDL to metabolise membrane lipid hydroperoxides. Diabetic Med 2008;25:1049-55
   PubMedGoogle Scholar
• Jakubowski H. Protein homocysteinylation: possible mechanisms underlying pathological consequences of elevated homocysteine levels. Faseb J 1999;13:2277-83
   PubMed Web of Science ®Google Scholar
• Jakubowski H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J Nutr 2000;130:377S-81S
   PubMed Web of Science ®Google Scholar
• Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase- a protective mechanism against protein s-homocysteinylation. J Biol Chem 2000;275:3957-62
   PubMed Web of Science ®Google Scholar
• Hine D, Mackness B, Mackness M. Co-incubation of PON1, APO A1 and LCAT increases the time HDL is able to prevent LDL oxidation. IUBMB Life 2012;64:157-61
   PubMed Web of Science ®Google Scholar
• Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011;121:2693-708
   PubMed Web of Science ®Google Scholar
• Liu M-L, Scalia R, Mehta JL, Williams KJ. Cholesterol-induced membrane microvesicles as novel carriers of damage-associated molecular patterns. Arterioscler Thromb Vasc Biol 2012;32:2113-21
   PubMedGoogle Scholar
• Schrader C, Rimbach G. Determinants of paraoxonase 1 status: genes, drugs and nutrition. Curr Med Chem 2011;18:5624-43
   PubMed Web of Science ®Google Scholar
• Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol 2011;81:337-44
   PubMed Web of Science ®Google Scholar
• Mackness B, Marsillach J, Elkeles RS, et al. Paraoxonase-1 is not associated with Coronary artery calcification in type 2 diabetes – results from the PREDICT study. Disease Markers 2012;33:101-12
   PubMedGoogle Scholar
• Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 1997;17:2935-9
   PubMed Web of Science ®Google Scholar
• Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000;20:516-21
   PubMed Web of Science ®Google Scholar
• Kim DS, Burt AA, Ranchalis JE, et al. Additional common polymorphisms in the PON gene cluster predict PON1 activity but not vascular disease. J Lipids 2012;2012:476316
   PubMedGoogle Scholar
• Richter RJ, Jarvik GP, Furlong CE. Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ Cardiovasc Genet 2008;1:147-52
   PubMed Web of Science ®Google Scholar
• Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009;46:83-106
   PubMed Web of Science ®Google Scholar
• Christison JK, Rye KA, Stocker R. Exchange of oxidised cholesteryl-linoleate between LDL and HDL mediated by cholesteryl ester transfer protein. J lipid Res 1995;36:2017-26
   PubMed Web of Science ®Google Scholar
• Mishra VK, Palgunachari MN, McPherson DT, Anantharamaiah GM. Lipid complex of apolipoprotein A1 mimetic peptide 4F is a novel platform for paraoxonase-1 binding and enhancing its activity. Biochem Biophys Res Comm 2013;430:975-80
   PubMedGoogle Scholar